FDA expands use of stool test from BD Diagnostics

01/12/2009 | Forbes

The FDA has allowed BD Diagnostics, a unit of Becton, Dickinson and Co., to sell a stool test for the "rapid detection" of a toxin that can cause clostridium difficile infection. The BD GeneOhm Cdiff molecular test, which could remove the need for multiple screenings, is already approved for use in spotting methicillin-resistant Staphylococcus aureus.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN